|
||
| |||||||
|
|
Solvo Biotechnology Announces Appointment of Bruno Stieger to the Strategic Advisory Board Budapest, Hungary – April 3rd, 2006: Solvo Biotechnology announced today the appointment of Bruno Stieger to its Strategic Advisory Board. Dr. Stieger is recognized as a global leader in the field of drug transporter science. “We are extremely pleased and deeply honored to have such a world leading scientist as Bruno Stieger join our Strategic Advisory Board,” said SOLVO’s President and CEO Mr Ernő Duda. Bruno Stieger, PhD is head of the research laboratory of the Institute of Clinical Pharmacology and Toxicology at the Department of Medicine, University Hospital, Zurich, Switzerland. He was trained as a biochemist at the Federal Institute of Technology in Zurich Switzerland from where he also received his PhD. His research interests are focused on physiological, biochemical and cell biological aspects of epithelia with a current focus on the liver. The Institute of Clinical Pharmacology and Toxicology of the University Hospital Zurich has cloned the major bile salt transport systems of hepatocytes including the sodium-dependent uptake system Ntcp (Slc10a1), several organic anion transporting polypeptides, which are additionally important drug transporters (members of the Slco transporter family) and the bile salt export pump Bsep (Abcb11). The current research interests of the Institute are related to i) understand the role of the interaction of drugs with transport systems in the development of acquired liver disease, ii) the role of genetic polymorphisms in rendering patients susceptible to acquired liver disease and the iii) the investigation of molecular mechanisms of canalicular bile formation. "Dr. Stieger is a leader of the world famous European school of membrane transporter science. We are very excited and look forward to working with him as a member of our new Strategic Advisory Board in the development and promotion of new drug transporter technologies that will help reduce the cost and time of drug development ," commented Dr. Peter Krajcsi, Chief Scientific Officer of Solvo Biotechnology. About Solvo Biotechnology Solvo Biotechnology - "The Transporter Company" has been the pioneer and the leader in the commercialization of Membrane Transporter technologies, including therapeutics, diagnostics and drug discovery assays. The company offers drug discovery products and services to pharmaceutical, biotechnology and consumer goods industries, relevant to many therapeutic areas and product categories. All major pharmaceutical and biotechnology companies use SOLVO's assays, either in-house, or as contracted research to significantly reduce the time and cost of the compound development process. By now, it is a common knowledge that efflux and various uptake transporters play key roles in the function of the Blood-Brain Barrier (BBB), the blood-CSF barrier, the blood-testis barrier, the intestinal epithelia (absorption), the airway epithelia, the liver epithelia and the kidney epithelia. SOLVO products can be used to study the transport properties of these pharmacological barriers. SOLVO's mainstream products are its High Throughput in vitro assay systems to detect the interaction of test compounds with a wide array of ABC Transporter proteins, and cell lines expressing various uptake transporter proteins used for in vitro ADME/Tox, oncology drug research and MDR modulating agent discovery. For additional information, please refer to the company's web site at www.solvo.com or call +36-23-503-937.
CONTACT: Gábor Heltovics Business Development Director Solvo Biotechnology +36-23-503-937 |
|
| ||||||||
